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“Viscosupplementation is the process that restores the
normal rheological environment in the synovial fluid,
synovial tissue…and reestablishes the protection,
lubrication, shock absorption and barrier effects.”








Hyaluronic acid:  
limitations and needs
 Low residency time
 Low to moderate clinical efficacy
 Not recommended in recent guidelines
 with a longer residency time
 a better clinical efficacy
a disease modifying effect


























A pilot open uncontrolled study
 30 patients with femoro-tibial OA
 2 ml containing 24 mg HA and 60 mg CS
 3 injections on a weekly basis


















80 % reach a clinical reponse according OARSI/OMERACT criteria
HA + CS
Biomarkers
∆T0 – T12 Trends
Coll2-1 (nM) -11 ± 78 ↓ Degradation
Coll2-1NO2 (nM) -0.06 ±0.41 ↓ Oxidative
stress
CS-846 (ng/ml) +1± 17 ↑ Synthesis
CPII ng/ml) -41± 867 ↓ Synthesis
IL-6 (pg/ml) -5667± 21769 ↓↓↓ Inflammation
Biomarkers changes suggest that HA/CS tends to  promote return to
cartilage homeostasis  
Diameter:  600-900 µm
 Mushroom Chitosan : 
0.5% - 42Kda









Ratio 1/1  w/w
Chitosan smartbeads®+ 






30 min @ 37°C 
Fluid @ room T° Gel formation @ 37°C 
Codevelopped wiht KitoZyme  
Study design
Day 7
Single  injection :
 900 µl Arthrovisc®  (n=7)
 900 µl Hydrogel alone (n=7)



















Arthrovisc® decreases OA 
progression
Radiography Histology
So…What’s about the future?
Perhaps not only a dream!
Conclusions
Thank you for your attention !
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